Komori
Perseus Proteomics (4882) · RiskMitigated

Risks of Patent Grant and Rights Protection, Obsolescence and Third-Party Use

First written in FY2021. 6 of 7 entries say "Mitigated", first in FY2022. Latest entry: 2026-07-03.

7entries
6years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2021MitigatedFY2022 – 2026-07-032021: 120212022: 120222023: 120232024: 020242025: 120252026: 32026
Same theme, other companies
Risk of weakened protection of the company's intellectual property and manufacturing know-howA theme 20 companies write about · 20 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2024: 3 of 7 companies on the "Worse" side.

3 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 20 companies compared. The sentences above are computed from all 20.
Full recordFilings, disclosures and news, newest first
  1. FY2025MitigatedAnnual report

    「At present, based on the investigations conducted, no patent rights or other rights have been identified that would impede or potentially impede the implementation of the Company's pipeline.」

    This reconfirms that general risks such as failure to obtain patents, technological obsolescence and third-party use remain, but no patent rights or other rights that would impede implementation of the current pipeline have been identified.
  2. FY2023MitigatedAnnual report

    「At present, based on the investigations conducted, no patent rights or other rights have been identified that would impede or potentially impede the implementation of the Company's pipeline.」

    This reconfirms that general risks such as failure to obtain patents and technological obsolescence remain, but no patent rights or other rights that would impede implementation of the current pipeline have been identified.
  3. FY2022MitigatedAnnual report

    「At present, based on the investigations conducted, no patent rights or other rights have been identified that would impede or potentially impede the implementation of the Company's pipeline.」

    This states that general risks such as failure to obtain patents and technological obsolescence remain, but no patent rights or other rights that would impede implementation of the current pipeline have been identified.
  4. FY2021First statedAnnual report

    「Not all patents may be granted for the inventions for which applications have been filed, and not all pending patent applications may result in the acquisition of patent rights. In addition, if superior technology emerges, the technology covered by the patents implemented by the Company may become obsolete.」

    This identifies as risks the failure to obtain patents or patent rights, technological obsolescence, loss of effectiveness due to third-party patents and use by third parties.
Moved together

"Drug Discovery through Joint Research with Universities and Research Institutions and Expansion of Contract Research" moved the same way as this thread, in the same document, in 3 of its 7 moves.

333333★123456
  1. ★This thread
  2. 1Drug Discovery through Joint Research with Universities and Research Institutions and Expansion of Contract Research3×
  3. 2Research on expanding PPMX-T003 indications to hematologic and solid cancers3×
  4. 3Expansion of antibody research support and sales of antibodies and reagents3×
  5. 4Research on Predicting Progression to Severe COVID-19 Using PTX33×
  6. 5Dependence on Fujifilm and Customer Concentration3×
  7. 6Risk of Share Price Decline Due to Sales of Shares Held by Venture Capital Firms3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Perseus Proteomics yet. It last moved in the Other Disclosures of 2026-07-03: "Mitigated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.